Allogene Therapeutics, Inc. — Form 8-K Summary
Reporting date: December 14, 2020; filed December 15, 2020. The filing reports entry into material definitive agreements relating to a new joint venture.
Business Context
Allogene Therapeutics and Overland Pharmaceuticals formed Allogene Overland Biopharm (CY) Limited to develop, manufacture and commercialize certain of Allogene’s allogeneic CAR T-cell therapies in China, Taiwan, South Korea and Singapore.
- Allogene acquired Seed Preferred shares representing 49% of the joint venture as partial consideration for granting the licenses.
- Overland acquired 51% for $117 million in upfront and certain quarterly cash payments.
- Of Overland’s $117 million contribution, $77 million is intended for joint-venture operating capital and $40 million is payable to Allogene under the license agreement.
Financial and Commercial Terms
| Item | Terms |
|---|---|
| Upfront payment to Allogene | $40 million |
| Development milestones | Up to $40 million |
| Royalties | Tiered low- to mid-single-digit royalties on net sales in the territory, subject to specified reductions |
| Ownership | Allogene 49%; Overland 51% |
| Licensed targets | BCMA, CD70, FLT3 and DLL3 |
Allogene retains exclusive rights to develop, manufacture and commercialize the licensed products outside the defined territory. Allogene also plans to supply ALLO-647, used in lymphodepletion regimens for certain CAR T-cell candidates, under a separate supply agreement.
The filing does not provide revenue, profit, cash-flow, margin, debt or liquidity metrics for the period.
Material Changes and Governance
- The joint venture board will have five directors: two designated by Allogene, two by Overland and the joint-venture chief executive officer.
- The parties received specified consent, information, registration and pre-emptive rights.
- The joint venture and license arrangements include customary representations, warranties, indemnities and intellectual-property licenses.
Outlook, Risks and Unusual Items
Future payments are contingent on the joint venture’s progress and the achievement of development milestones. The filing states that the joint venture’s ability to establish operations, advance clinical trials, manufacture and commercialize therapies, and receive or make expected payments is subject to execution and regulatory risks.
The license may be terminated for material breach, bankruptcy, certain patent challenges or, after a specified period, at the joint venture’s discretion with notice. Licensed rights generally terminate upon termination of the license. Allogene’s forward-looking statements are subject to risks described in its other SEC filings, including its Form 10-Q for the quarter ended September 30, 2020.
Investor Verification Items
- Verify the final executed Share Purchase Agreement, Shareholders’ Agreement and License Agreement when filed as exhibits to Allogene’s 2020 Form 10-K.
- Confirm the timing and accounting treatment of the $40 million upfront payment and any future milestone payments.
- Review the detailed royalty reductions, milestone definitions, supply terms for ALLO-647 and termination provisions.
- Assess the joint venture’s funding needs, operating performance and regulatory progress in each territory.
- Monitor whether licensed candidates advance clinically and whether any milestone or royalty payments are actually received.